Exothera adds continuous upstream bioprocessing tech to services

By The Science Advisory Board staff writers

January 28, 2021 -- Contract development and manufacturing organization Exothera has acquired the NevoLine Upstream manufacturing platform, the latest equipment available from Univercells Technologies.

Exothera will use the NevoLine platform for the manufacturing of viral vector-based gene therapies and viral vaccines. The technology works through intensification and chaining of unit steps into a continuous process, which allows users to achieve high yields. The platform increases volumetric production, offering significant development and production cost reductions.

NevoLine.
The NevoLine Upstream platform. Image courtesy of Univercells Technologies.

The platform is an integrated and automated solution for cost-effective production of viral vaccines, viral vectors, and oncolytic viruses. The equipment will be installed within its 9,690-sq-ft good manufacturing practice (GMP) facility based in Jumet, Belgium. The site will have dedicated upstream and downstream process development production areas, as well as clinical and commercial GMP manufacturing capabilities. At the same site, a second 59, 200-sq-ft GMP facility will open in January 2022.

Exothera offers process development, viral vector support to biomanufacturers
Biomanufacturing company Univercells announced on March 19 that it has established a contract development and manufacturing organization named Exothera...

Copyright © 2021 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter